REPORTS & DISCLOSURES
Medical Marijuana, Inc.
Introduced to investors in March of 2009, Medical Marijuana, Inc. is the first company entirely within the cannabis business space to be traded on public stock markets.
Being traded publicly on the stock exchange is a milestone for any new industry and serves to normalize cannabis as an industry. The creation of Medical Marijuana, Inc. was featured in the CNBC documentary Marijuana, Inc., the most watched program in station history.
With over 200,000 current shareholders, the widespread public investment in our company is a show of support for Medical Marijuana, Inc. and the cannabis industry at large.
Part of our core mission is making cannabis available to as much of the world’s population as possible, and we have persevered in extending “access to all” in every step our company takes.
A worldwide cannabinoid market can help people around the globe achieve better health. While some prefer cannabinoids to more well known medications for their lack of side effects, others have discovered that cannabinoids produce results that traditional pharmaceuticals have not been able to provide. A wider market also allows us to lower consumer costs, keeping our products accessible to those who need it most.
HempMeds® Brasil, a subsidiary of Medical Marijuana, Inc., became the first company to have a cannabis product, Real Scientific Hemp Oil™(RSHO™), prescribed for a number of indications when it was exported to Brazil for all forms of epilepsy, Alzheimer’s disease, Parkinson’s disease, chronic pain and migraines. Real Scientific Hemp Oil™ continues to be prescribed for more indications, as the Brazilian medical community becomes more educated about the benefits of cannabinoids. While providing access to CBD medications for patients now, Medical Marijuana, Inc. is working with health authorities in Brazil to further develop the market for cannabidiol in the country.
Medical Marijuana, Inc. subsidiary Kannalife™ Sciences holds the first two licenses awarded to develop and commercialize drug treatments under the U.S. government’s only cannabinoid patent. Kannalife™ Sciences is a phyto-medical company specializing in the research and development of cannabinoid based pharmaceuticals. With nearly a dozen decorated researchers on their Scientific Advisory Board and a leadership team that features decades of experience in the pharmaceutical space, including the development of orphan drugs, Kannalife™ is in a unique position to capitalize on these licenses.
This article may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties.
FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE
These statements have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease. Always check with your physician before starting a new dietary supplement program.
* Cannabidiol (CBD) is a naturally-occurring constituent of the industrial hemp plant.
Medical Marijuana Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). The company does grow, sell and distribute hemp based products.